Anesthesia and analgesia
-
Anesthesia and analgesia · Oct 1998
Randomized Controlled Trial Multicenter Study Clinical TrialPostoperative analgesic effects of three demand-dose sizes of fentanyl administered by patient-controlled analgesia.
Many studies have demonstrated the postoperative analgesic efficacy of fentanyl delivered i.v. by patient-controlled analgesia (PCA) devices at demand doses ranging from 10 to 50 microg, but none has sought to define the optimal fentanyl PCA dose. In this randomized, double-blind, multicenter study, we compared the safety and efficacy of three administered demand-dose sizes of fentanyl (20, 40, and 60 microg) in 150 patients after major surgery. Efficacy was dose-dependent; positive response rates (i.e., a global assessment score of "very good" or "excellent" and the absence of severe opioid adverse effects) were 42%, 52%, and 68% for the 20, 40, and 60 microg demand-dose groups, respectively, and were significantly higher in the 60 microg demand-dose group. The number of doses administered and missed attempts were significantly smaller in the 40 and 60 microg demand-dose groups compared with the 20 microg demand-dose group. This suggests that the 20 microg demand dose provided inadequate pain relief. Adverse respiratory events were more frequent and mean respiratory rates were significantly slower with the 60 microg demand dose, compared with the 20 or 40 microg demand doses. These results indicate that, of these three doses, the 40 microg demand dose was optimal for fentanyl PCA management of moderate to severe pain after major surgery. ⋯ The postoperative analgesic efficacy of fentanyl delivered i.v. by patient-controlled analgesia devices has been demonstrated for demand doses ranging from 10 to 50 microg, but the optimal fentanyl dose remains unknown. In this randomized, double-blind study, we compared three demand dose sizes of fentanyl (20, 40, and 60 microg) and found that the 40 microg demand dose was the most appropriate for fentanyl patient-controlled analgesia management of postoperative pain.
-
Anesthesia and analgesia · Oct 1998
The analgesic potency of dexmedetomidine is enhanced after nerve injury: a possible role for peripheral alpha2-adrenoceptors.
This study investigated the analgesic potency and site of action of systemic dexmedetomidine, a selective alpha2-adrenoceptor (alpha2AR) agonist, in normal and neuropathic rats. Ligation of the L5-6 spinal nerves produced a chronic mechanical and thermal neuropathic hyperalgesia in rats. von Frey fibers and a thermoelectric Peltier device were used to measure mechanical and heat withdrawal thresholds over the hindpaw. Systemic dexmedetomidine dose-dependently increased the mechanical and thermal thresholds in the control animals (50% effective dose [ED50] 144 and 180 microg/kg intraperitoneally [i.p.], respectively). Neuropathic animals responded to much smaller doses of dexmedetomidine with mechanical and thermal ED50 values of 52 and 29 microg/kg i.p., respectively. There was no difference between the control and neuropathic animals with respect to dexmedetomidine-evoked sedation, as determined by decreased grid crossings in an open-field activity chamber (ED50 12 and 9 microg/kg i.p., respectively). Atipamezole, a selective alpha2AR antagonist, blocked the analgesic and sedative actions of dexmedetomidine inboth the neuropathic and control animals. However, L-659,066, a peripherally restricted alpha2AR antagonist, could only block the analgesic actions of dexmedetomidine in the neuropathic rats, with no effect in control animals. In conclusion, nerve injury enhanced the analgesic but not the sedative potency of systemic dexmedetomidine and may have shifted the site of alpha2 analgesic action to outside the blood-brain barrier. ⋯ We tested the analgesic efficacy of the alpha2 agonist dexmedetomidine in normal and nerve-injured rats. The analgesic potency of dexmedetomidine was enhanced after nerve injury with a site of action outside the central nervous system. Peripherally restricted alpha2 agonists may be useful in the management of neuropathic pain.
-
Anesthesia and analgesia · Oct 1998
Comment Letter Case ReportsRelief of chronic refractory hiccups with glossopharyngeal nerve block.
-
Anesthesia and analgesia · Oct 1998
Randomized Controlled Trial Clinical TrialCryoanalgesia: effect on postherniorrhaphy pain.
Cryoanalgesia versus sham treatment was applied to the ilioinguinal and iliohypogastric nerves after mesh repair of an inguinal hernia under local anesthesia in 48 male patients in a prospective, randomized, and observer- and patient-blinded trial. Pain was scored daily during rest, while coughing, and during mobilization to the sitting position for 1 wk and weekly for 8 wk on a four-point verbal rank scale. Use of supplementary analgesics and sensory disturbances were recorded. Assessments were made for allodynia, hyperalgesia, and mechanical pain detection thresholds 8 wk postoperatively. Cumulative pain scores for the first postoperative week were equal in the two groups, as was the use of analgesics. Eight weeks postoperatively, three cases of hyperalgesia to pinprick were detected in the cryoanalgesia group, and 10 patients in the cryoanalgesia group versus 5 in the sham-treatment group reported disturbed sensibility. We conclude that cryoanalgesia of the iliohypogastrical and ilioinguinal nerve does not decrease postherniorrhaphy pain. ⋯ Does freezing of sensory nerves in the groin reduce pain after hernia repair? Extreme cold (-60 degrees C) was applied in a double-blind, randomized study. No difference in pain scores was found. Sensory disturbances were seen in treatment and control patients. Freezing cannot be recommended for pain relief after hernia repair.
-
Anesthesia and analgesia · Oct 1998
Randomized Controlled Trial Comparative Study Clinical TrialSingle-dose tropisetron for preventing postoperative nausea and vomiting after breast surgery.
In this randomized, double-blind, placebo-controlled study, we compared the efficacy of tropisetron 5 mg with tropisetron 2 mg for the prevention of postoperative nausea and vomiting (PONV) after breast surgery. One hundred forty-eight female patients were randomized to receive either tropisetron 5 mg (n = 49), tropisetron 2 mg (n = 49), or saline (n = 50) before the induction of anesthesia with thiopental and morphine. Anesthesia was maintained with nitrous oxide and isoflurane. Postoperative analgesia was provided by patient-controlled analgesia with i.v. morphine. The incidence of PONV, the pain score, and the analgesic requirement were recorded for 48 h. There was no difference among groups in patient characteristics, risk factors for PONV, morphine consumption, or side effects. During the first 6 h postoperatively, the incidence of PONV after tropisetron 2 mg and 5 mg were similar and were superior to placebo (P < 0.001). After 6 h, the incidence of PONV increased significantly in patients who had received tropisetron 2 mg (P = 0.01) and was greater than that in patients who had received tropisetron 5 mg (P = 0.001). We conclude that single-dose tropisetron 5 mg is more effective than tropisetron 2 mg in the prevention of PONV after breast surgery. ⋯ Breast surgery is associated with a high incidence of postoperative nausea and vomiting. A single dose of i.v. tropisetron 5 mg is well tolerated and decreases the number of vomiting and nausea episodes after surgery.